Atrium Therapeutics Inc Revenue Growth Rates (RNA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Atrium Therapeutics Inc   (NASDAQ: RNA)
 

RNA's Revenue Growth by Quarter and Year

Atrium Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RNA/growth
https://api.csimarket.com/api/v1/companies/RNA/fundamentals
https://api.csimarket.com/api/v1/companies/RNA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RNA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.32
2nd Quarter June 3.00
1st Quarter March 19.64
FY 37.96

RNAs Annual Revenue
Atrium Therapeutics Inc 's Revenue in the fiscal year 2025 $ 18.76 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2024 $ 10.90 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2023 $ 9.56 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2022 $ 9.22 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2021 $ 9.33 millions




RNA Revenue third quarter 2026 Y/Y Growth Comment
Atrium Therapeutics Inc reported Revenue improvement of 22.76% year on year in the third quarter 2026, to $ 15.32 millions, this is lower than Atrium Therapeutics Inc 's recent average Revenue surge of 104.33%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 162 other companies have achieved higher Revenue growth. While Atrium Therapeutics Inc ' s Revenue rise of 22.76% ranks overall at the positon no. 3545 in the third quarter 2026.


RNA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 22.76 %
2nd Quarter June -22.08 %
1st Quarter March 1150.96 %
FY   -

Financial Statements
Atrium Therapeutics Inc 's third quarter 2026 Revenue $ 15.32 millions RNA's Income Statement
Atrium Therapeutics Inc 's third quarter 2025 Revenue $ 12.48 millions Quarterly RNA's Income Statement


RNA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 410.7 %
2nd Quarter June -84.73 %
1st Quarter March 2183.72 %
FY (Year on Year)   -


Back to RNA Growth rate Comparisons >> Back to RNA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #163
Healthcare Sector #488
Overall #3545

Revenue Y/Y Growth Statistics
High Average Low
1148.25 % 104.33 % -71.07 %
(Mar 31 2026)   (Mar 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #163
Healthcare Sector #488
Overall #3545
Revenue Y/Y Growth Statistics
High Average Low
1148.25 % 104.33 % -71.07 %
(Mar 31 2026)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Atrium Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2183.14 % 98.67 % -93.11 %
(Mar 31 2026)  


RNA's III. Quarter Q/Q Revenue Comment
Atrium Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 410.7%, to $ 15.32 millions, from $3.00 millions in the second quarter.
RNA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 206 other companies have achieved higher Revenue quarter on quarter growth. While Atrium Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3911.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #207
Healthcare Sector #578
Overall #3911
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #207
Healthcare Sector #578
Overall #3911
Revenue Q/Q Growth Statistics
High Average Low
2183.14 % 98.67 % -93.11 %
(Mar 31 2026)  


RNA's III. Quarter Q/Q Revenue Comment
Atrium Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 410.7%, to $ 15.32 millions, from $3.00 millions in the second quarter.
RNA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 206 other companies have achieved higher Revenue quarter on quarter growth. While Atrium Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3911.


Atrium Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 35.97
Y / Y Revenue Growth (TTM) 235.3 %
Year on Year Revenue Growth Overall Ranking # 2523
Seqeuential Revenue Change (TTM) -2.29 %
Seq. Revenue Growth (TTM) Overall Ranking # 858


Cumulative Revenue growth Comment
Assuming the Atrium Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Atrium Therapeutics Inc would have reprted above average annual Revenue surge of 235.3% year on year, of $ 36 millions.
This marks a slow-down of the companys growth trends and from the 312.42% surge in Mar 31 2026.

In the Healthcare sector 363 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2523, from total ranking in previous quarter at 3282.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 364
Overall # 2523

Revenue TTM Y/Y Growth Statistics
High Average Low
312.42 %
 49.24 %
-17.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 68
Sector # 174
S&P 500 # 858
Cumulative Revenue growth Comment
Assuming the Atrium Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Atrium Therapeutics Inc would have reprted above average annual Revenue surge of 235.3% year on year, of $ 36 millions.
This marks a slow-down of the companys growth trends and from the 312.42% surge in Mar 31 2026.

In the Healthcare sector 363 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2523, from total ranking in previous quarter at 3282.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 364
Overall # 2523

Revenue TTM Y/Y Growth Statistics
High Average Low
312.42 %
49.24 %
-17.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 68
Sector # 174
S&P 500 # 858




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RNA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions


About Atrium Therapeutics Inc Revenue Growth Rates (RNA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Avidity Biosciences Inc (CIK 1599901).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001599901-26-000031
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Avidity Biosciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.